Cadrenal Therapeutics Completes FDA Phase 2 Meeting, Advances CAD-1005 to Phase 3 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Cadrenal Therapeutics announced a regulatory milestone after completing its End-of-Phase 2 meeting with the FDA and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the company's investigational first-in-class 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia. The meeting with the FDA provided critical guidance on protocol design, study population, dosing, background therapy, exposure, the safety database, and the primary endpoint of new or worsening thrombotic events. After considering FDA feedback on a pivotal registration study, Cadrenal plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to the current standard of care for patients with HIT.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cadrenal Therapeutics Q1 Financial Results
- Net Loss Reported: Cadrenal Therapeutics reported a net loss of $2.5 million for Q1 2026, indicating challenges in profitability that could impact investor confidence and future funding capabilities.
- Cash Position: As of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million, reflecting tight liquidity that may limit ongoing operations and research and development activities.
- Financial Transparency: The company's release of financial information and historical earnings data provides investors with a clearer view of its financial status, although the current losses may raise concerns about long-term sustainability.
- Market Reaction Anticipation: Following the earnings report, the market may focus more on Cadrenal's future development direction and financing strategies, especially in the current economic climate where investors will be more cautious in assessing risks associated with biotech firms.
See More
Cadrenal Therapeutics Reports Q1 2026 Financial Results and CAD-1005 Program Update
- FDA Meeting Outcomes: Cadrenal Therapeutics received critical trial design guidance from the FDA during its EOP2 meeting, planning to advance directly to a randomized, blinded, placebo-controlled Phase 3 trial for CAD-1005, which is expected to support a New Drug Application submission in 2029.
- Clinical Trial Scale: The planned Phase 3 study will enroll approximately 120 patients to evaluate the efficacy of CAD-1005 added to standard anticoagulation, with the primary endpoint being the incidence of new or worsening thrombotic events, showcasing the company's strategic foresight in HIT treatment.
- R&D Expense Reduction: Research and development expenses for Q1 2026 were $0.8 million, significantly down from $1.7 million in Q1 2025, indicating progress in cost control, while the net loss decreased to $2.5 million, reflecting an improvement in financial health.
- Financing Support: Following the end of Q1 2026, Cadrenal completed a $2.5 million financing, providing essential capital for the upcoming Phase 3 clinical trial, further solidifying its market position in HIT treatment.
See More
Cadrenal Advances CAD-1005 to Phase 3 Trial Following FDA Clearance
- FDA Approval for Phase 3: Cadrenal Therapeutics' CAD-1005 has received FDA clearance to advance into a Phase 3 randomized controlled trial for heparin-induced thrombocytopenia, with plans to enroll approximately 120 patients, indicating a significant strategic advancement in the development of new therapies.
- Phase 2 Trial Data: Although the Phase 2 trial missed its primary endpoint, CAD-1005 demonstrated over a 25% reduction in thrombotic events when combined with standard anticoagulant therapy, suggesting its potential clinical value and the possibility of transforming HIT treatment.
- Pipeline Expansion: Cadrenal is expanding its 12-LOX drug pipeline while maintaining a focus on CAD-1005; early research indicates that targeting the 12-LOX pathway may have applications in obesity and diabetes, enhancing the company's competitive position in the market.
- Retail Sentiment Surge: Retail sentiment for CVKD reached a record high of 99/100 on Stocktwits, reflecting strong investor confidence in the company's future despite a 62% decline in stock price over the past year, highlighting market expectations for its new therapy.
See More
CAD-1005 Advances to Pivotal Phase 3 Clinical Trial
- Regulatory Milestone: Cadrenal Therapeutics achieved a significant milestone by receiving critical guidance from the FDA during its EOP2 meeting, successfully advancing CAD-1005 into pivotal Phase 3 trials, marking a major step in treating heparin-induced thrombocytopenia (HIT).
- Trial Design: The planned Phase 3 study will enroll approximately 120 patients across 50 clinical centers worldwide, aiming to evaluate the efficacy of CAD-1005 in conjunction with standard anticoagulant therapy, with a projected NDA submission in 2029.
- Efficacy Data: Phase 2 trial results indicated that the addition of CAD-1005 led to over a 25% absolute reduction in thrombotic events, demonstrating its potential to improve patient outcomes and possibly becoming the first new therapy in over two decades.
- Market Potential: As the first novel treatment targeting HIT, CAD-1005 has received Orphan Drug and Fast Track designations, positioning it to fill a significant market gap for the over 12 million patients receiving heparin annually in the U.S.
See More
H.C. Wainwright Lowers Target Price for Cadrenal Therapeutics Inc. to $13 from $32
- Company Overview: Cadrénal Therapeutics is a company focused on developing innovative therapies.
- Recent Price Adjustment: The target price for Cadrénal Therapeutics has been cut from $32 to $13.
See More
Cadrenal Therapeutics Reports FY Losses
- Financial Performance: Cadrenal Therapeutics reported a FY GAAP EPS of -$6.64, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, Cadrenal had cash and cash equivalents of $4 million, suggesting increased liquidity pressure on the company to maintain operations, potentially necessitating measures to ensure ongoing viability.
- Market Reaction: The reported losses have led to a cautious market outlook on Cadrenal's future prospects, likely resulting in stock price volatility and influencing investor decision-making.
- Investor Focus: Analysts and investors will closely monitor Cadrenal's subsequent financial performance and strategic responses to assess whether the company can reverse its current financial difficulties and achieve sustainable growth.
See More
Cadrenal Therapeutics Q1 Financial Results
- Net Loss Reported: Cadrenal Therapeutics reported a net loss of $2.5 million for Q1 2026, indicating challenges in profitability that could impact investor confidence and future funding capabilities.
- Cash Position: As of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million, reflecting tight liquidity that may limit ongoing operations and research and development activities.
- Financial Transparency: The company's release of financial information and historical earnings data provides investors with a clearer view of its financial status, although the current losses may raise concerns about long-term sustainability.
- Market Reaction Anticipation: Following the earnings report, the market may focus more on Cadrenal's future development direction and financing strategies, especially in the current economic climate where investors will be more cautious in assessing risks associated with biotech firms.
See More
Cadrenal Therapeutics Reports Q1 2026 Financial Results and CAD-1005 Program Update
- FDA Meeting Outcomes: Cadrenal Therapeutics received critical trial design guidance from the FDA during its EOP2 meeting, planning to advance directly to a randomized, blinded, placebo-controlled Phase 3 trial for CAD-1005, which is expected to support a New Drug Application submission in 2029.
- Clinical Trial Scale: The planned Phase 3 study will enroll approximately 120 patients to evaluate the efficacy of CAD-1005 added to standard anticoagulation, with the primary endpoint being the incidence of new or worsening thrombotic events, showcasing the company's strategic foresight in HIT treatment.
- R&D Expense Reduction: Research and development expenses for Q1 2026 were $0.8 million, significantly down from $1.7 million in Q1 2025, indicating progress in cost control, while the net loss decreased to $2.5 million, reflecting an improvement in financial health.
- Financing Support: Following the end of Q1 2026, Cadrenal completed a $2.5 million financing, providing essential capital for the upcoming Phase 3 clinical trial, further solidifying its market position in HIT treatment.
See More
Cadrenal Advances CAD-1005 to Phase 3 Trial Following FDA Clearance
- FDA Approval for Phase 3: Cadrenal Therapeutics' CAD-1005 has received FDA clearance to advance into a Phase 3 randomized controlled trial for heparin-induced thrombocytopenia, with plans to enroll approximately 120 patients, indicating a significant strategic advancement in the development of new therapies.
- Phase 2 Trial Data: Although the Phase 2 trial missed its primary endpoint, CAD-1005 demonstrated over a 25% reduction in thrombotic events when combined with standard anticoagulant therapy, suggesting its potential clinical value and the possibility of transforming HIT treatment.
- Pipeline Expansion: Cadrenal is expanding its 12-LOX drug pipeline while maintaining a focus on CAD-1005; early research indicates that targeting the 12-LOX pathway may have applications in obesity and diabetes, enhancing the company's competitive position in the market.
- Retail Sentiment Surge: Retail sentiment for CVKD reached a record high of 99/100 on Stocktwits, reflecting strong investor confidence in the company's future despite a 62% decline in stock price over the past year, highlighting market expectations for its new therapy.
See More
CAD-1005 Advances to Pivotal Phase 3 Clinical Trial
- Regulatory Milestone: Cadrenal Therapeutics achieved a significant milestone by receiving critical guidance from the FDA during its EOP2 meeting, successfully advancing CAD-1005 into pivotal Phase 3 trials, marking a major step in treating heparin-induced thrombocytopenia (HIT).
- Trial Design: The planned Phase 3 study will enroll approximately 120 patients across 50 clinical centers worldwide, aiming to evaluate the efficacy of CAD-1005 in conjunction with standard anticoagulant therapy, with a projected NDA submission in 2029.
- Efficacy Data: Phase 2 trial results indicated that the addition of CAD-1005 led to over a 25% absolute reduction in thrombotic events, demonstrating its potential to improve patient outcomes and possibly becoming the first new therapy in over two decades.
- Market Potential: As the first novel treatment targeting HIT, CAD-1005 has received Orphan Drug and Fast Track designations, positioning it to fill a significant market gap for the over 12 million patients receiving heparin annually in the U.S.
See More
H.C. Wainwright Lowers Target Price for Cadrenal Therapeutics Inc. to $13 from $32
- Company Overview: Cadrénal Therapeutics is a company focused on developing innovative therapies.
- Recent Price Adjustment: The target price for Cadrénal Therapeutics has been cut from $32 to $13.
See More
Cadrenal Therapeutics Reports FY Losses
- Financial Performance: Cadrenal Therapeutics reported a FY GAAP EPS of -$6.64, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, Cadrenal had cash and cash equivalents of $4 million, suggesting increased liquidity pressure on the company to maintain operations, potentially necessitating measures to ensure ongoing viability.
- Market Reaction: The reported losses have led to a cautious market outlook on Cadrenal's future prospects, likely resulting in stock price volatility and influencing investor decision-making.
- Investor Focus: Analysts and investors will closely monitor Cadrenal's subsequent financial performance and strategic responses to assess whether the company can reverse its current financial difficulties and achieve sustainable growth.
See More
